Thalidomide-O-C6-COOH

Background Introduction

Thalidomide-O-C6-COOH is a specialized E3 ligase ligand-linker conjugate used primarily in the development of PROTACs (Proteolysis Targeting Chimeras). This compound consists of a thalidomide derivative, a clinically validated E3 ligase ligand, attached to a 6-carbon linker featuring a terminal carboxylic acid group. This structural design enables straightforward conjugation to various target protein ligands, making it a versatile tool in chemical biology and drug discovery.

Mechanism

Thalidomide-O-C6-COOH operates by leveraging the selective binding of thalidomide to the CRBN (cereblon) E3 ubiquitin ligase. The thalidomide moiety recruits CRBN, while the C6 linker and carboxylic acid handle facilitate covalent attachment to ligands targeting specific proteins of interest. Once conjugated, the resulting PROTAC molecule brings the target protein into proximity with CRBN E3 ligase, leading to ubiquitination and subsequent proteasomal degradation of the target protein. This targeted protein degradation mechanism enables selective and efficient removal of disease-related proteins within cells.

Applications

Thalidomide-O-C6-COOH is widely used for the synthesis of CRBN-based PROTACs in both academic research and pharmaceutical development. Its applications include the construction of bifunctional degraders for target validation, studying protein function via degradation, and discovering novel therapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Moreover, the terminal carboxylic acid group allows flexible conjugation chemistry, enabling medicinal chemists to rapidly generate PROTAC libraries for high-throughput screening and structure-activity relationship (SAR) studies.

The E3 Ligase Ligand-Linker Conjugate, Thalidomide-O-C6-COOH, plays a crucial role in the development of PROTACs by facilitating selective protein degradation. It offers advantages such as enhanced specificity and reduced off-target effects. This description explores the linker, ligand, and target protein ligand selection, providing a detailed overview of the molecule's components for academic research.

Linker: The linker in Thalidomide-O-C6-COOH is a hexyl chain, providing moderate length and flexibility. Its non-cleavable nature ensures stability in cellular environments, allowing for efficient proximity-induced degradation of the target protein.

Ligand: The ligand is based on thalidomide, a well-characterized E3 ligase recruiter. Its structural characteristics include a glutarimide moiety, which effectively binds to the cereblon E3 ligase, facilitating the ubiquitination and subsequent degradation of target proteins.

Reactive Site: The reactive site is the carboxylic acid group at the terminus of the hexyl chain. This site is suitable for coupling with target protein ligands via amide bond formation, enhancing the stability and efficacy of the resulting PROTAC.

Recommended Target Protein Ligand: The recommended warhead for this conjugate is a small molecule inhibitor with an amine functional group, allowing for efficient amide bond formation. This configuration enhances the selectivity and potency of the PROTAC, making it ideal for research focused on degrading specific proteins involved in disease pathways, thereby advancing targeted protein degradation studies.